Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic?

J Hypertens. 2020 May;38(5):781-782. doi: 10.1097/HJH.0000000000002450.

Authors

Murray Esler¹, Danielle Esler²

Affiliations

¹ Baker Heart and Diabetes Institute.
² Public Health Directorate, Northern Territory Department of Health, and Honorary Research Fellow Baker Heart and Diabetes Institute, Melbourne, Australia.

PMID: 32195824
DOI: 10.1097/HJH.0000000000002450

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Angiotensin Receptor Antagonists / adverse effects*
Angiotensin-Converting Enzyme 2
Antihypertensive Agents / adverse effects*
Betacoronavirus / physiology*
Blood Pressure
COVID-19
COVID-19 Drug Treatment
Coronavirus Infections / complications*
Coronavirus Infections / drug therapy
Coronavirus Infections / virology
Humans
Hypertension / drug therapy
Pandemics
Peptidyl-Dipeptidase A / blood*
Pneumonia, Viral / complications*
Pneumonia, Viral / virology
Receptors, Virus
SARS-CoV-2
Spike Glycoprotein, Coronavirus
Virus Internalization

Substances

Angiotensin Receptor Antagonists
Antihypertensive Agents
Receptors, Virus
Spike Glycoprotein, Coronavirus
spike protein, SARS-CoV-2
Peptidyl-Dipeptidase A
ACE2 protein, human
Angiotensin-Converting Enzyme 2